A Landscape Analysis of Laboratory Technologies for Covid-19 Response in Low and Middle-Income Countries (LMICs): Equipment, Reagents, and Supplies for Diagnostic Molecular, Antigen and Serological Testing

Diagnostic tests for Covid-19 fall into three main categories: Molecular, Antigen, and Serological. Each category of tests comes with its own limitations, thus impacting how and where it can be used. Molecular tests based on Polymerase Chain Reaction (PCR) technology are the current ‘gold standard’ for Covid-19 testing. However, their accuracy is determined by the viral load in an infected individual. They may miss out detecting individuals at early stages of infection and lower viral load. Similarly, serology and antigen tests have other important performance issues.

What are these limitations and thresholds for each of the technologies? How do these technologies work?

This landscape analysis provides the technological details of Covid-19 testing technologies based on review of available literature. Highlighting the performance and appropriate use of available technologies, it is a complementary decision-support tool to the test dashboard.

 

Download Report

 


 

DISCLAIMER:

Due the dynamic nature of diagnostics market, this documentation and information will be updated periodically.

MSH and The Rockefeller Foundation do not guarantee the accuracy, completeness or integrity of the information collected from the secondary data sources and interviewees.  Further, the information is provided for informational purposes only and is not intended as an endorsement, guidance, recommendations, or advice for any particular product, program or policy. Any use or interpretation of or reliance on the information for any purpose, is solely and exclusively the responsibility of the recipients of the information. THE INFORMATION IS PROVIDED “AS IS”. NO WARRANTY OF ANY KIND IS GIVEN FOR THE INFORMATION UNDER ANY NATIONAL OR INTERNATIONAL LAW, INCLUDING WARRANTY AGAINST INFRINGEMENT OF INTELLECTUAL PROPERTY. MSH AND THE ROCKEFELLER FOUNDATION expressly disclaim and assume no responsibility for any losses, damages, claims, or other liabilities, including loss of good will, revenue, profits, or business interruption, or any consequential, special, indirect, incidental, punitive or exemplary loss, including costs of defense or attorneys’ fees, arising out of or relating to use of this information. It is expressly understood that the MSH and The Rockefeller Foundation, by providing this information, have no obligation to update the information or provide additional support or information to the recipient.

 

Related Updates

Dec 02 2020
 
Covid-19 Diagnostic Resources for Low- and Middle-Income Countries
More
Dec 02 2020
 
Dashboards | Covid-19 Diagnostics
More
Dec 02 2020
 
Supply Chain Guidance | Covid-19 Diagnostics
More
Back to Top